Last reviewed · How we verify
CD19 CAR-T Cell Infusion as Consolidation Therapy in Adolescent and Adult Patients With Acute B-ALL Ineligible for Allogeneic HSCT: A Clinical Study
This clinical study investigates a novel treatment option for adolescents and adults with acute B-lymphoblastic leukemia (B-ALL). While allogeneic hematopoietic stem cell transplantation (HSCT) is a standard therapy for leukemia, some patients are ineligible due to factors such as age, underlying medical conditions, or the absence of a suitable donor. For these individuals, CD19 CAR-T cell therapy is being evaluated as a potential consolidation therapy.
Details
| Lead sponsor | Zhujiang Hospital |
|---|---|
| Phase | PHASE1, PHASE2 |
| Status | RECRUITING |
| Enrolment | 30 |
| Start date | Sat Jul 19 2025 00:00:00 GMT+0000 (Coordinated Universal Time) |
| Completion | Thu Aug 19 2027 00:00:00 GMT+0000 (Coordinated Universal Time) |
Conditions
- Acute Lymphoblastic Leukemia
Interventions
- CD19 CAR-T cells injection
Countries
China